Dengue Vaccine Trends and Forecast
The future of the global dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 12.1% from 2024 to 2030. The major drivers for this market are escalating prevalence of dengue fever and rising R&D activities for vaccine development across the globe.
Lucintel forecasts that anti-allergic segment is expected to witness the highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those that occur after a dengue vaccination.
Within this market, hospitals will remain the largest segment due to increasing healthcare services including immunizations and a growing focus towards preventative care and the need for higher-quality healthcare services.
APAC is expected to witness the highest growth over the forecast period due to rising government expenditure to develop better healthcare infrastructures in the region.
A more than 150-page report is developed to help in your business decisions.
Emerging Trends in the Dengue Vaccine Market
The developing dengue vaccine industry has been witnessing several emerging trends that are reshaping this market. These trends emerging in the market have technological advancements that are present in the vaccine, shifts in people’s health concerns and changes in market structure.
• Broader Serotype Coverage: An interest is growing in the development of vaccines that will protect against all four dengue virus serotypes. It is vital in preventing severe dengue in the targeted populations.
• Improved Vaccine Safety: The effort is directed towards enhancing the safety level of available dengue vaccines, to leave no chance of their acceptance declining or support levels remaining stagnant. This includes the safe and efficacious vaccines, that undergo proper clinical development and are keen on post marketing follow-up.
• Integration with Existing Health Systems: There is also a trend to extend vaccine coverage by incorporating vaccination against dengue within the routine health care services, especially in the areas where the endemics are. Vaccination campaigns targeting the populations at risk of infection are also quite hard to be implemented and adherence is often low.
• Vaccine Delivery through Different Routes: Further investigations and attempts are made to administer the vaccines via easy access routes such as oral routes and needle free systems for better compliance and for heightened vaccination coverage.
• Increased Global Collaboration: Worldwide, there is an expanding collaboration involving governments, pharmaceutical companies and health agencies for the development of vaccines against diseases in order to create an environment where there is fair distribution of the vaccines produced.
These emerging trends are changing the landscape of the dengue vaccine market via enhanced vaccine effectiveness, enhanced safety, and improved accessibility. The quest for increased serotype coverage and effective delivery mechanisms, as well as the global consolidation of partnership are making great strides towards the realization of effective dengue prevention strategies.
Recent Developments in the Dengue Vaccine Market
Market trends in recent times regarding dengue vaccines show notable progress concerning vaccine research, production, and integration into health systems. Such changes are sequential as they all work towards tackling the global mounting challenge of dengue fever and its prevention.
• Innovative Vaccine Formulations: Work is underway to formulate vaccines against all four serotypes of the dengue virus as there is little progress in combating the disease with current innovative advances in vaccination strategies.
• Increased Approval by Regulatory Agencies: There have been several approvals of dengue vaccines in the countries where the disease occurs, making it possible to use these vaccines and making them more accessible in the areas where the disease is prevalent.
• Safety Enhancements: Dengue vaccine safety has been a concern for a long time and recent strategies are focused on enhancing the safety of new dengue vaccines being developed such that new vaccine candidates have a lower chance of having side effects than previous vaccines in clinical trials.
• Public Immunization Program Inclusion: The pursuit of including the dengue vaccine in the routine immunization schedule of countries is on the rise. This also works towards ensuring vaccine delivery systems are efficient and vaccines are available in areas of high disease risk.
• Partnerships Cross-Bordering for Research: The research and development of the dengue vaccine is being made easier and faster through global collaboration. Governments, drug manufacturers, and agencies combating global health issues are working together to develop and roll out vaccines.
These three aspects are catering the dengue vaccine market by enhancing the formulations of vaccines, promoting the regulatory processes and more importantly, safety of the vaccines contained in the formulations. In addition, progress in the integration of vaccines into public health programmes and global research initiatives is also advancing and addressing the problems of dengue prevention.
Strategic Growth Opportunities for Dengue Vaccine Market
The dengue vaccine market holds many strategic growth opportunities across different application sectors and has favorable prospects. These opportunities reflects the potential of vaccine clinical research and vaccine commercial development and distribution.
• Expansion in Endemic Regions: There is a market expansion opportunity in increasing the coverage of dengue and related diseases vaccination programs in areas endemic for dengue. A targeted approach to such areas could make the health interventions more rewarding and lower the disease burden.
• Development of Affordable Vaccines: Development of cheap vaccines is very critical in increasing availability on that affordable countries that are classified as lower-middle and middle-income countries. Cheap vaccines can improve take up and address health inequity challenges.
• Innovations in Vaccine Delivery: There are expansion opportunities for growing such means that will employ other non-injection rendering of the vaccine like oral vaccine or needle free systems. Such approaches can enhance the acceptability of vaccines and their administration as well as solve some of the problems of mass immunization.
• Integration with existing immunization programs: Completion of existing immunization services for other diseases by adding the provision of dengue vaccines can reduce wastage of resources and the total effort required for the provision of vaccines. Such approaches can improve the effect of vaccination programs.
• Collaborating with Global Health Organizations: Engagement of global health agencies and partnerships involving governmental and non-governmental entities can stimulate R&D efforts, allow for vaccine distribution and advocate for worldwide vaccination programs.
These strategic business development opportunities indicate the prospect for creativity and development in the market for the dengue vaccine. The focus on endemic areas, low-cost, alternate modes of delivery, easy incorporation with immunization programs, and collaboration worldwide will bring greater benefits to stakeholders in dengue vaccination.
Dengue Vaccine Market Driver and Challenges
The vigorous growth of the global market for dengue vaccine market is subject to varietal technological, economic, and regulatory factors. Knowing these triggers and barriers is important in order to operate in the market and look for chances and possibilities.
The factors responsible for driving the dengue vaccine market include:
1. Technological Advancements: Introduction of advanced technologies such as tetravalent vaccines is expanding the market. This includes the development of dengue vaccines effective against all four types aimed at improving market performance.
2. Rising Incidence of Dengue Fever: The rising occurrence of dengue fever cases in areas where the disease is endemic creates a fair market for better vaccines. There is thus rising desperation for reasons as to why better preventive measures against the disease are needed, hence growing the market.
3. Global Health Initiatives: The activities of these international organizations as well as the strategies to fight against the dengue fever amount to reasons for R&D. There is greater vaccine development and vaccine distribution as a result of bush funding and exploitation.
4. Enhanced Vaccine Safety: The positive changes in vaccine safety profiles lead to more widespread adoption with the public becoming more confident in their usage. More acceptance of vaccination will result in safer and more effective disease control.
5. Integration to Existing Public Health Programs: The inclusion of dengue vaccines into national immunization programs enhances the uptake and the control of disease within known hotspots.
Challenges in the dengue vaccine market are:
1. High Development Costs: The price associated with the research and development, and manufacture of dengue vaccine is relatively high; this makes it difficult for most companies hence some people may not be able to access these in poor areas.
2. Regulatory Hurdles: Regulatory processes for obtaining approvals and ensuring adherence with the different standards established by different countries could prove to take a longer time.
3. Disease Burden Variable: More than one serotype of dengue virus exists and the geographic region in which the vaccine is targeted may also differ in terms of disease burden. Such factors make it difficult in either developing or distributing the vaccine.
4. Access Distribution: Reaching the target populations with vaccines and resolving access issues in non-urban or low-income areas are critical to improving vaccine utilization.
5. Public Acceptance: Vaccine acceptance by the public and management of vaccine hesitancy is essential in ensuring high uptake of vaccines as a measure in the control of diseases.
The dengue vaccine market is expanding as a result of several factors such as advancements in technology, increased incidences, public health initiatives, enhanced safety and integration into public health. However, factors such as high development costs, regulatory barriers, epidemiology variability, access and perception issues are hurdles that need to be sorted out. Addressing these factors in absolute terms is important for the success of the dengue vaccine interventions and growth of the market.
List of Dengue Vaccine Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dengue vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dengue vaccine companies profiled in this report include-
• Mylan
• BIO-MED
• Teva Pharmaceutical
• Sanofi
• Novartis
• GSK
• F. Hoffmann-La Roche
Dengue Vaccine by Segment
The study includes a forecast for the global dengue vaccine by type, treatment, distribution channel, end use, and region.
Dengue Vaccine Market by Type [Analysis by Value from 2018 to 2030]:
• Live Attenuated Vaccine
• Chimeric Live Attenuated Vaccine
• Inactivated Vaccine
• Subunit Vaccine
• Nucleic Acid Based Vaccine
Dengue Vaccine Market by Treatment [Analysis by Value from 2018 to 2030]:
• Diuretic
• Anti-Allergic
• Blood Thinners
• Others
Dengue Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
Dengue Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:
• Hospitals
• Homecare
• Specialty Clinics
• Others
Dengue Vaccine Market by Region [Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Dengue Vaccine Market
The dengue vaccine market is constantly adapting because policymakers and drug manufacturers have been making efforts to address the issues posed by dengue fever, which is a viral illness that is causatively transmitted by mosquitoes in the tropical and subtropical regions of the world. Current developments are recent innovative regulatory submissions, rapid increase in king approval of vaccine researcher, and amplification in public health programs aimed at the management of dengue incidences. These changes are about a growing request for effective intervention methods and improving knowledge of the epidemiology of the disease.
• United States: In the U.S. there has been vaccination against dengue and there have been advances in the clinical trials of dengue vaccines. And there have been advances in the clinical trials of these bank ultrasound glucose lowering agent. The Assault has been on creating safer and more effective vaccines with sounder b cell immune primes and multiple serotype coverage. Similarly, in the U.S efforts are attempting to assist regenerative medicine in the development of affordable vaccines by collaborating with Global institutes managing sex disease epidemics.
• China: Several candidates are currently in clinical trials, indicating that China has made important accomplishments in dengue vaccine development. The country is focused on high-priority doling to yen remain terrenie communities the dengue shocks targeting mathematic four Pieryyic patients-comprising four de.Publish culture enabling new technologies for pressurized sprayers. In addition, China is expanding the vaccine manufacturing capacity and development s policies to include the dengue vaccine into the primary healthcare system.
• Germany: To the degree, in addition to the above, Germany is researching and cooperating in the global Dengue vaccine search and market. There include recent steps in vaccination progress and vaccine safety evaluation. In addition, German country pharmaceutical practices are providing strategic collaborations with global organizations on the dissemination of dengue vaccines in endemic countries.
• India: In India as a case in consideration, affordable and effective dengue vaccines are being developed to mitigate the disease burden that the population is facing. Country other last-minute pointers that include looking out for restrictions need to adapt to domestically manufactured vaccines and the use of the nationally integrated vaccination program. There is also focus in India on strengthening surveillance systems and improving vaccine coverage in the areas at specific risks.
• Japan: There are also other countries theoretically involved in the dengue vaccine search and development some of them include Japan which have made fresh developments like it is construction and testing of new vaccine delivery systems.
Features of the Global Dengue Vaccine Market
Market Size Estimates: Dengue vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Dengue vaccine market size by various segments, such as by type, treatment, distribution channel, end use, and region in terms of ($B).
Regional Analysis: Dengue vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, treatments, distribution channels, end uses, and regions for the dengue vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dengue vaccine market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q.1 What is the dengue vaccine market size?
Answer: The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030.
Q.2 What is the growth forecast for dengue vaccine market?
Answer: The global dengue vaccine market is expected to grow with a CAGR of 12.1% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the dengue vaccine market?
Answer: The major drivers for this market are escalating prevalence of dengue fever and rising R&D activities for vaccine development across the globe.
Q4. What are the major segments for dengue vaccine market?
Answer: The future of the dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.
Q5. Who are the key dengue vaccine market companies?
Answer: Some of the key dengue vaccine companies are as follows:
• Mylan
• BIO-MED
• Teva Pharmaceutical
• Sanofi
• Novartis
• GSK
• F. Hoffmann-La Roche
Q6. Which dengue vaccine market segment will be the largest in future?
Answer: Lucintel forecasts that anti-allergic segment is expected to witness the highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those that occur after a dengue vaccination.
Q7. In dengue vaccine market, which region is expected to be the largest in next 5 years?
Answer: APAC is expected to witness the highest growth over the forecast period due to rising government expenditure to develop better healthcare infrastructures in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the dengue vaccine market by type (live attenuated vaccine, chimeric live attenuated vaccine, inactivated vaccine, subunit vaccine, and nucleic acid based vaccine), treatment (diuretic, anti-allergic, blood thinners, and others), distribution channel (hospital pharmacy, online pharmacy, and retail pharmacy), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Dengue Vaccine Market, Dengue Vaccine Market Size, Dengue Vaccine Market Growth, Dengue Vaccine Market Analysis, Dengue Vaccine Market Report, Dengue Vaccine Market Share, Dengue Vaccine Market Trends, Dengue Vaccine Market Forecast, Dengue Vaccine Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.